

# CONTENTS

---

## VOLUME 1

<b>About the Editor</b>	<b>xxi</b>
<b>Contributors</b>	<b>xxiii</b>
<b>Preface</b>	<b>xxxix</b>
<b>Acknowledgments</b>	<b>xxxv</b>
<b>Editor's Note</b>	<b>xxxvii</b>

### **PART I: FUNDAMENTALS OF HERBAL MEDICINE**

<b>Chapter 1. History and Regulation of Botanicals in the United States</b>	<b>3</b>
<i>Loren D. Israelsen</i>	
<i>Marilyn Barrett</i>	
Introduction	3
History	3
DSHEA Explained	5
Drugs: OTC and Rx	10
Prospectus	11
<b>Chapter 2. Product Definition Deficiencies in Clinical Studies of Herbal Medicines</b>	<b>13</b>
<i>Varro E. Tyler</i>	
<b>Chapter 3. Identifying and Characterizing Botanical Products</b>	<b>23</b>
<i>Marilyn Barrett</i>	
Identifying Plants by Name	24
Means of Assuring Plant Identity	26
Preparations and Formulations	30
Dose	30
Bioavailability	30
Guidelines	31
Appendix: Preparations and Formulations	32

<b>Chapter 4. Standardization of Botanical Preparations: What It Does and Does Not Tell Us</b>	<b>37</b>
<i>Uwe Koetter</i>	
<i>Marilyn Barrett</i>	
Introduction	37
Standardization of Therapeutic Activity	38
Standardization to Meet a Chemical Norm	39
Standardization As a Reflection of Quality	
Assurance Programs	41
Guidance	43
Situation in the Marketplace	44
Perspective	45
<b>Chapter 5. The Importance and Difficulty in Determining the Bioavailability of Herbal Preparations</b>	<b>49</b>
<i>Anton Biber</i>	
<i>Friedrich Lang</i>	
<b>Chapter 6. “Borrowed Science” and “Phytoequivalence”: Can Two Herbal Products Be Judged Equivalent?</b>	<b>59</b>
<i>Marilyn Barrett</i>	
Chemical or Pharmaceutical Equivalency	61
Bioequivalency or Therapeutic Equivalency	62
Application of the Concepts, Ginkgo As an Example	63
Meta-Analyses	65
Perspective	66
<b>Chapter 7. Determining Efficacy of Herbal Preparations</b>	<b>69</b>
<i>Tieraona Low Dog</i>	
Observational Medicine	70
“Evidence-Based” Medicine	71
Summary	74
<b>Chapter 8. Evaluating Safety of Herbal Preparations</b>	<b>77</b>
<i>Ezra Béjar</i>	
<i>Joseph M. Betz</i>	
<i>Marilyn Barrett</i>	
Evaluation of Safety	78
Adverse Reactions	80
Adverse-Event Reporting Systems	81
Categorization According to the Degree of Safety	82

Product Quality As an Aspect of Safety	84
Contraindications	85
Drug-Herb Interactions	85
Improving Our Knowledge of Safety	87
<b>Chapter 9. Conducting Clinical Trials on Herbal Dietary Supplements in North America: Commercialization, Confidence, and Conflicts</b>	<b>91</b>
<i>Anthony L. Almada</i>	
The Spirit to Sponsor: Is There an Adequate Economic Incentive to Fund Research?	92
Extracting Value from Science	95
Competitor Kevlar: Preventing Piracy of Product-Specific Data	96
How Much Data Is Enough?	100
We Have Data—Now What?	103
Who Has Science and How Did They Acquire It?	105
Conclusion	105
<b>Chapter 10. Motives for Conducting Clinical Trials on Botanicals in Europe: A Focus on Germany</b>	<b>107</b>
<i>Joerg Gruenwald</i>	
<i>Stefan Spiess</i>	
<b>Chapter 11. Pharmacopoeias and Botanical Monographs</b>	<b>115</b>
<i>Marilyn Barrett</i>	
<i>Roy Upton</i>	
<i>V. Srinivasi</i>	
<i>United States Pharmacopeia and National Formulary (USP-NF)</i>	116
<i>American Herbal Pharmacopoeia (AHP) and Therapeutic Compendium</i>	118
<i>European Pharmacopoeia (EP)</i>	119
<i>British Herbal Pharmacopoeia (BHP) and British Herbal Compendium (BHC)</i>	119
German Commission E	120
European Scientific Cooperative on Phytotherapy (ESCOP)	121
<i>Chinese Pharmacopoeia</i>	121
<i>African Pharmacopoeia</i>	122
<i>The Pharmacopoeia of Japan</i>	122
The Pharmacopoeias of India	123



World Health Organization (WHO)	123
Other Pharmacopoeias	124
Summary and Perspective	124
Sources of Pharmacopoeias	125

## PART II: METHODS

<b>Chapter 12. Methods of Product and Trial Inclusion and Evaluation</b>	<b>129</b>
<i>Marilyn Barrett</i>	
Gathering Information on Products and Trials	129
Data on Products and Trials	134
Evaluation of Clinical Trial Quality	137
<b>Chapter 13. Clinical Trial Reviewer's Guidance and Checklist</b>	<b>141</b>
<i>Tieraona Low Dog</i>	
Levels of Evidence	141
Guidelines for Reviewer Checklist: Part I	142
Guidelines for Reviewer Checklist: Part II	144
Scoring	146

## PART III: BOTANICAL PROFILES— PRODUCT AND CLINICAL TRIAL INFORMATION (Artichoke–Ginseng)

<i>Single Herbs</i>	<b>151</b>
<b>Artichoke</b>	<b>151</b>
Preparations Used in Reviewed Clinical Studies	151
Artichoke Summary Table	152
Summary of Reviewed Clinical Studies	153
Postmarketing Surveillance Studies	154
Adverse Reactions or Side Effects	154
Information from Pharmacopoeial Monographs	155
Details on Artichoke Products and Clinical Studies	157
<b>Bilberry</b>	<b>163</b>
Preparations Used in Reviewed Clinical Studies	163
Bilberry Summary Table	164

Summary of Reviewed Clinical Studies	165
Adverse Reactions or Side Effects	167
Information from Pharmacopoeial Monographs	168
Details on Bilberry Products and Clinical Studies	171
<b>Black Cohosh</b>	<b>185</b>
Preparations Used in Reviewed Clinical Studies	185
Black Cohosh Summary Table	186
Summary of Reviewed Clinical Studies	187
Postmarketing Surveillance Studies	189
Adverse Reactions or Side Effects	189
Information from Pharmacopoeial Monographs	190
Details on Black Cohosh Products and Clinical Studies	194
<b>Boxwood</b>	<b>207</b>
Preparations Used in Reviewed Clinical Studies	207
Summary of Reviewed Clinical Studies	207
Boxwood Summary Table	208
Adverse Reactions or Side Effects	209
Details on Boxwood Products and Clinical Studies	210
<b>Butterbur, Purple</b>	<b>213</b>
Preparations Used in Reviewed Clinical Studies	213
Butterbur Summary Table	214
Summary of Reviewed Clinical Studies	215
Adverse Reactions or Side Effects	216
Information from Pharmacopoeial Monographs	216
Details on Butterbur Products and Clinical Studies	218
<b>Cat's Claw</b>	<b>225</b>
Preparations Used in Reviewed Clinical Studies	225
Cat's Claw Summary Table	226
Summary of Reviewed Clinical Studies	227
Adverse Reactions or Side Effects	227
Details on Cat's Claw Products and Clinical Studies	228



<b>Chaste Tree</b>	<b>231</b>
Preparations Used in Reviewed Clinical Studies	231
Chaste Tree Summary Table	232
Summary of Reviewed Clinical Studies	233
Postmarketing Surveillance Studies	235
Adverse Reactions or Side Effects	236
Information from Pharmacopoeial Monographs	236
Details on Chaste Tree Products and Clinical Studies	240
<b>Cordyceps</b>	<b>255</b>
Preparations Used in Reviewed Clinical Studies	255
Summary of Reviewed Clinical Studies	255
Cordyceps Summary Table	256
Adverse Reactions or Side Effects	258
Information from Pharmacopoeial Monographs	258
Details on Cordyceps Products and Clinical Studies	260
<b>Cranberry</b>	<b>265</b>
Preparations Used in Reviewed Clinical Studies	265
Summary of Reviewed Clinical Studies	265
Cranberry Summary Table	266
Adverse Reactions or Side Effects	267
Information from Pharmacopoeial Monographs	268
Details on Cranberry Products and Clinical Studies	270
<b>Devil's Claw</b>	<b>277</b>
Preparations Used in Reviewed Clinical Studies	277
Summary of Reviewed Clinical Studies	277
Devil's Claw Summary Table	278
Adverse Reactions or Side Effects	280
Information from Pharmacopoeial Monographs	280
Details on Devil's Claw Products and Clinical Studies	283
<b>Dragon's Blood Croton</b>	<b>291</b>
Preparations Used in Reviewed Clinical Studies	291
Dragon's Blood Croton Summary Table	292
Summary of Reviewed Clinical Studies	293

Adverse Reactions or Side Effects	293
Details on Dragon's Blood Products and Clinical Studies	295
<b>Echinacea</b>	<b>303</b>
Preparations Used in Reviewed Clinical Studies	303
Echinacea Summary Table	304
Summary of Reviewed Clinical Studies	307
Reviews and Meta-Analyses of Clinical Studies	311
Adverse Reactions or Side Effects	312
Information from Pharmacopoeial Monographs	313
Details on Echinacea Products and Clinical Studies	321
<b>Elderberry</b>	<b>351</b>
Preparations Used in Reviewed Clinical Studies	351
Elderberry Summary Table	352
Summary of Reviewed Clinical Studies	353
Adverse Reactions or Side Effects	353
Information from Pharmacopoeial Monographs	353
Details on Elderberry Products and Clinical Studies	356
<b>Evening Primrose</b>	<b>359</b>
Preparations Used in Reviewed Clinical Studies	359
Evening Primrose Summary Table	360
Summary of Reviewed Clinical Studies	362
Systematic Reviews and Meta-Analyses	367
Adverse Reactions or Side Effects	368
Details on Evening Primrose Products and Clinical Studies	370
<b>Garlic</b>	<b>403</b>
Preparations Used in Reviewed Clinical Studies	403
Garlic Summary Table	404
Summary of Reviewed Clinical Studies	408
Meta-Analyses and Systematic Clinical Reviews	419
Epidemiological Studies	421
Adverse Reactions or Side Effects	421
Information from Pharmacopoeial Monographs	422
Details on Garlic Products and Clinical Studies	429



<b>Ginger</b>	<b>493</b>
Preparations Used in Reviewed Clinical Studies	493
Ginger Summary Table	494
Summary of Reviewed Clinical Studies	495
Systematic Reviews and Meta-Analyses	501
Adverse Reactions or Side Effects	501
Information from Pharmacopoeial Monographs	502
Details on Ginger Products and Clinical Studies	508
<b>Ginkgo</b>	<b>547</b>
Preparations Used in Reviewed Clinical Studies	547
Ginkgo Summary Table	548
Summary of Reviewed Clinical Studies	551
Meta-Analyses and Systematic Reviews	562
Adverse Reactions or Side Effects	565
Information from Pharmacopoeial Monographs	566
Details on Ginkgo Products and Clinical Studies	575
<b>Ginseng</b>	<b>673</b>
Preparations Used in Reviewed Clinical Studies	673
Ginseng Summary Table	674
Summary of Reviewed Clinical Studies	676
Systematic Reviews	683
Epidemiological Studies	683
Adverse Reactions or Side Effects	684
Information from Pharmacopoeial Monographs	685
Details on Ginseng Products and Clinical Studies	691

---